Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase III, Open-Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin's Lymphoma Evaluating the Benefit of GA101 (RO5072759) Plus Chemotherapy Compared With Rituximab Plus Chemotherapy Followed by GA101 or Rituximab Maintenance Therapy in Responders

NCT01332968 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01332968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01332968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase III, Open-Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin's Lymphoma Evaluating the Benefit of GA101 (RO5072759) Plus Chemotherapy Compared With Rituximab Plus Chemotherapy Followed by GA101 or Rituximab Maintenance Therapy in Responders
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
July 6, 2011
Completion date
July 30, 2021
Enrollment
1,401 (actual)
Sites
183

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma